Pyc Therapeutics Ltd has released a press release.
Change of Managing Director
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
Earlier from PYC Therapeutics
- ADOA Program - Presentation of Clinical Data at NOSA 2025
- PKD Program - Presentation of Safety Data at ANZSN
- Appendix 4E
- Approval to Escalate Dosing in Kidney Disease Clinical Trial
- Approval to Progress Kidney Disease Trial to Next Stage
Later from PYC Therapeutics
- Correction to Trading Halt Request
- Board and Management Changes
- ADOA Program Progressing to Multiple Dose Study
- PMS Program Data Supports Progression to Human Trials
- ADOA Program Initiation of Global Repeat Dose Study
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics